前列腺癌的免疫治疗：一种新兴的治疗方式。
Immunotherapy for prostate cancer: an emerging treatment modality.
机构信息
Departments of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, 1650 Orleans Street CRB I #410, Baltimore, MD 21231, USA.
出版信息
Urol Clin North Am. 2010 Feb;37(1):121-9, Table of Contents. doi: 10.1016/j.ucl.2009.11.001.
Abstract
This article examines prostate cancer as a target for immunotherapy and investigates active immunotherapy for prostate cancer, combining conventional therapy with active immunotherapy, immune modulators (brakes and accelerators), and monoclonal antibodies.
摘要
本文探讨了前列腺癌作为免疫治疗的靶点，并研究了主动免疫疗法在前列腺癌中的应用，将常规疗法与主动免疫疗法、免疫调节剂（抑制剂和激活剂）以及单克隆抗体相结合。
相似文献
1
Immunotherapy for prostate cancer: an emerging treatment modality.前列腺癌的免疫治疗：一种新兴的治疗方式。
Urol Clin North Am. 2010 Feb;37(1):121-9, Table of Contents. doi: 10.1016/j.ucl.2009.11.001.
2
Prostate cancer: Towards effective combination of ADT and immunotherapy.前列腺癌：迈向雄激素剥夺疗法与免疫疗法的有效联合
Nat Rev Urol. 2016 Jun;13(6):300. doi: 10.1038/nrurol.2016.80. Epub 2016 Apr 26.
3
Emerging role of immunotherapy in the management of prostate cancer.免疫疗法在前列腺癌治疗中的新作用。
Oncology (Williston Park). 2007 Mar;21(3):326-33; discussion 334, 338, 346-8.
4
Advances in specific immunotherapy for prostate cancer.前列腺癌特异性免疫疗法的进展。
Eur Urol. 2008 Apr;53(4):694-708. doi: 10.1016/j.eururo.2007.11.043. Epub 2007 Nov 26.
5
[Immunotherapy of prostate cancer].[前列腺癌的免疫疗法]
Urologe A. 1993 Sep;32(5):382-9.
6
The synergy between ionizing radiation and immunotherapy in the treatment of prostate cancer.电离辐射与免疫疗法在前列腺癌治疗中的协同作用。
Immunotherapy. 2017 Sep;9(12):1005-1018. doi: 10.2217/imt-2017-0051.
7
Immunotherapy and prostate cancer.免疫疗法与前列腺癌。
Cancer Treat Rev. 2003 Jun;29(3):199-209. doi: 10.1016/s0305-7372(03)00005-7.
8
Revisiting Immunotherapy: A Focus on Prostate Cancer.重新审视免疫疗法：聚焦前列腺癌。
Cancer Res. 2020 Apr 15;80(8):1615-1623. doi: 10.1158/0008-5472.CAN-19-2948. Epub 2020 Feb 17.
9
Immunotherapy and gene therapy in prostate cancer treatment.前列腺癌治疗中的免疫疗法和基因疗法。
J Med Life. 2017 Jan-Mar;10(1):54-55.
10
Sipuleucel-T and immunotherapy in the treatment of prostate cancer.西妥昔单抗 -T与免疫疗法治疗前列腺癌
Expert Opin Biol Ther. 2014 May;14(5):709-19. doi: 10.1517/14712598.2014.896897. Epub 2014 Mar 12.
引用本文的文献
1
Clinical implications of PTEN loss in prostate cancer.PTEN 缺失在前列腺癌中的临床意义。
Nat Rev Urol. 2018 Apr;15(4):222-234. doi: 10.1038/nrurol.2018.9. Epub 2018 Feb 20.
2
Feasibility of Applying Helper-Dependent Adenoviral Vectors for Cancer Immunotherapy.应用辅助依赖型腺病毒载体进行癌症免疫治疗的可行性。
Biomedicines. 2014 Mar 10;2(1):110-131. doi: 10.3390/biomedicines2010110.
3
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.依匹木单抗联合放疗对比安慰剂用于多西他赛化疗后进展的转移性去势抵抗性前列腺癌患者（CA184-043）：一项多中心、随机、双盲、III 期临床试验。
Lancet Oncol. 2014 Jun;15(7):700-12. doi: 10.1016/S1470-2045(14)70189-5. Epub 2014 May 13.
4
Immunotherapy for the treatment of prostate cancer.免疫疗法治疗前列腺癌。
Nat Rev Clin Oncol. 2011 May 24;8(9):551-61. doi: 10.1038/nrclinonc.2011.72.
5
Development of an MHC class I L(d)-restricted PSA peptide-loaded tetramer for detection of PSA-specific CD8+ T cells in the mouse.开发一种 MHC I 类 L(d)限制性 PSA 肽负载的四聚体，用于检测小鼠中的 PSA 特异性 CD8+ T 细胞。
Prostate Cancer Prostatic Dis. 2011 Jun;14(2):118-21. doi: 10.1038/pcan.2010.57. Epub 2011 Jan 25.
本文引用的文献
1
Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo.OX40共刺激受体的结扎可在体内逆转自身抗原和肿瘤诱导的CD8 T细胞无反应性。
Eur J Immunol. 2009 Aug;39(8):2184-94. doi: 10.1002/eji.200939348.
2
Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+.人前列腺浸润性CD8 + T淋巴细胞是寡克隆性且表达程序性死亡受体1（PD - 1）的。
Prostate. 2009 Nov 1;69(15):1694-703. doi: 10.1002/pros.21020.
3
Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer.编码前列腺酸性磷酸酶的DNA疫苗在D0期前列腺癌患者中的安全性和免疫疗效。
J Clin Oncol. 2009 Sep 1;27(25):4047-54. doi: 10.1200/JCO.2008.19.9968. Epub 2009 Jul 27.
4
Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients.去势抵抗性前列腺癌患者前列腺内免疫细胞浸润的特征分析
J Immunol Methods. 2009 Aug 31;348(1-2):9-17. doi: 10.1016/j.jim.2009.06.004. Epub 2009 Jun 22.
5
Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.普罗文塔夫-VF：一种针对前列腺癌 PSA 的基于载体的疫苗。
Expert Opin Investig Drugs. 2009 Jul;18(7):1001-11. doi: 10.1517/13543780902997928.
6
Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model.环磷酰胺增强抗肿瘤免疫：在原位前列腺癌模型中的研究。
Cancer Res. 2009 May 15;69(10):4309-18. doi: 10.1158/0008-5472.CAN-08-4102. Epub 2009 May 12.
7
Tumor recognition and self-recognition induce distinct transcriptional profiles in antigen-specific CD4 T cells.肿瘤识别和自身识别在抗原特异性CD4 T细胞中诱导出不同的转录谱。
J Immunol. 2009 Apr 15;182(8):4675-85. doi: 10.4049/jimmunol.0803400.
8
Myeloid-derived suppressor cells: linking inflammation and cancer.髓源性抑制细胞：连接炎症与癌症
J Immunol. 2009 Apr 15;182(8):4499-506. doi: 10.4049/jimmunol.0802740.
9
Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters.前列腺癌病灶被FOXP3+、PD-1+和B7-H1+淋巴细胞簇包围。
Eur J Cancer. 2009 Jun;45(9):1664-72. doi: 10.1016/j.ejca.2009.02.015. Epub 2009 Mar 21.
10
Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.通过CTLA4阻断和GM-CSF联合免疫疗法增强前列腺癌的内源性抗肿瘤免疫力。
Cancer Res. 2009 Jan 15;69(2):609-15. doi: 10.1158/0008-5472.CAN-08-3529.
Zotero 插件